Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 4, 2022
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
[ Mon, Apr 04th 2022
] - WOPRAI
Sun, April 3, 2022
Fri, April 1, 2022
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
[ Fri, Apr 01st 2022
] - WOPRAI
Salveen Richter Maintained (TSHA) at Strong Buy with Decreased Target to $27 on, Apr 1st, 2022
Salveen Richter of Goldman Sachs, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy with Decreased Target from $34 to $27 on, Apr 1st, 2022.
Salveen has made no other calls on TSHA in the last 4 months.
There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 0 agree with Salveen's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Salveen
- Jack Allen of "Baird" Initiated at Buy and Held Target at $26 on, Wednesday, March 9th, 2022
- Yanan Zhu of "Wells Fargo" Initiated at Buy and Held Target at $25 on, Tuesday, March 1st, 2022
- Debjit Chattopadhyay of "Guggenheim" Initiated at Strong Buy and Held Target at $28 on, Thursday, December 16th, 2021
